New Delhi: India’s pharmaceutical exports soared past the $30 billion mark in the financial year 2024-25, registering a robust growth of over 9 percent compared to the previous fiscal year, according to official trade data. This achievement underscores the sector’s sustained global demand and strong performance.
The United States continued to be the largest destination for Indian pharmaceutical products, accounting for more than one-third of the country’s total exports. In value terms, exports to the US witnessed a significant growth of over 14 percent during the year.
The data also revealed an impressive performance in March 2025, with monthly exports rising by over 30 percent year-on-year. Pharma exports for the month stood at $3.68 billion, up from $2.81 billion in March 2024.
Apart from the US, other major export destinations included the United Kingdom, Brazil, France, and South Africa, highlighting India’s wide-reaching presence in the global pharmaceutical market.
The continued growth in pharmaceutical exports reflects India’s expanding capabilities in drug manufacturing and supply, reinforcing its position as a global pharmacy hub.
